KR102863374B1 - 트리아졸로피리미딘 화합물 및 암 치료에서의 그의 용도 - Google Patents

트리아졸로피리미딘 화합물 및 암 치료에서의 그의 용도

Info

Publication number
KR102863374B1
KR102863374B1 KR1020207035470A KR20207035470A KR102863374B1 KR 102863374 B1 KR102863374 B1 KR 102863374B1 KR 1020207035470 A KR1020207035470 A KR 1020207035470A KR 20207035470 A KR20207035470 A KR 20207035470A KR 102863374 B1 KR102863374 B1 KR 102863374B1
Authority
KR
South Korea
Prior art keywords
methyl
triazolo
trimethyl
pyrrolidin
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207035470A
Other languages
English (en)
Korean (ko)
Other versions
KR20210013078A (ko
Inventor
프레드릭 울프 골드버그
아틸라 쿠안 추에이 팅
질리언 맥그리거 라몬트
데이비드 부타르
제이슨 그랜트 케틀
Original Assignee
디잘 (지앙수) 파마슈티칼 씨오., 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 디잘 (지앙수) 파마슈티칼 씨오., 리미티드 filed Critical 디잘 (지앙수) 파마슈티칼 씨오., 리미티드
Publication of KR20210013078A publication Critical patent/KR20210013078A/ko
Application granted granted Critical
Publication of KR102863374B1 publication Critical patent/KR102863374B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020207035470A 2018-05-11 2019-05-10 트리아졸로피리미딘 화합물 및 암 치료에서의 그의 용도 Active KR102863374B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862670075P 2018-05-11 2018-05-11
US62/670,075 2018-05-11
PCT/EP2019/062020 WO2019215316A1 (en) 2018-05-11 2019-05-10 Triazolopyrimidine compounds and their use in treating cancer

Publications (2)

Publication Number Publication Date
KR20210013078A KR20210013078A (ko) 2021-02-03
KR102863374B1 true KR102863374B1 (ko) 2025-09-22

Family

ID=66484070

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207035470A Active KR102863374B1 (ko) 2018-05-11 2019-05-10 트리아졸로피리미딘 화합물 및 암 치료에서의 그의 용도

Country Status (16)

Country Link
US (3) US11084827B2 (https=)
EP (2) EP4134368A1 (https=)
JP (1) JP7418353B2 (https=)
KR (1) KR102863374B1 (https=)
CN (3) CN112469721B (https=)
AR (1) AR115384A1 (https=)
AU (1) AU2019264826B2 (https=)
BR (1) BR112020023068A2 (https=)
CA (1) CA3099579A1 (https=)
DK (1) DK3790879T3 (https=)
ES (1) ES2927244T3 (https=)
MX (1) MX2020012058A (https=)
PT (1) PT3790879T (https=)
TW (1) TWI823932B (https=)
UY (1) UY38228A (https=)
WO (1) WO2019215316A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI823932B (zh) * 2018-05-11 2023-12-01 中國大陸商迪哲（江蘇）醫藥有限公司 三唑并嘧啶化合物及其在治療癌症中之用途
WO2021174176A1 (en) * 2020-02-28 2021-09-02 Remix Therapeutics Inc. Pyridazine dervatives for modulating nucleic acid splicing
US20230192704A1 (en) * 2020-05-21 2023-06-22 Teon Therapeutics, Inc. Monocarboxylic acid transporter 4 (mct4) modulators and uses thereof
WO2021249969A1 (en) * 2020-06-10 2021-12-16 Merck Patent Gmbh Combination product for the treatment of cancer diseases
WO2022090527A1 (en) 2020-11-02 2022-05-05 Ares Trading S.A. Combination treatment of cancer
WO2022243573A1 (en) 2021-05-21 2022-11-24 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 1,2,4-triazolo[1,5-a]pyrimidine-based slc16a3 inhibitors and their therapeutic use
WO2022243574A1 (en) 2021-05-21 2022-11-24 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 3-(phthalazin-1-yl)benzenesulfonamide-based slc16a3 inhibitors and their therapeutic use
CN120699024A (zh) * 2024-03-25 2025-09-26 北京福元医药股份有限公司 Mct4抑制剂及其药物组合物和用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072746A1 (en) 2001-10-16 2004-04-15 Michael Sullivan Inhibitors of monocarboxylate transport
WO2011114148A1 (en) 2010-03-17 2011-09-22 Astrazeneca Ab 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists
WO2017196936A1 (en) 2016-05-12 2017-11-16 Regents Of The University Of Minnesota Indole and indazole cyanocinnamate compounds and therapeutic uses thereof
JP2018502874A (ja) 2015-01-22 2018-02-01 ザ スクリプス リサーチ インスティテュート プテリジンジオンモノカルボン酸トランスポータ阻害薬

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0300119D0 (sv) 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
DE102005034905A1 (de) 2005-07-26 2007-02-01 Federal-Mogul Nürnberg GmbH Verfahren zur Herstellung eines Kolbens für einen Verbrennungsmotor sowie Kolben für einen Verbrennungsmotor
WO2010089580A1 (en) 2009-02-06 2010-08-12 Astrazeneca Ab Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
CA2974697A1 (en) * 2015-01-22 2016-07-28 The Scripps Research Institute Pyrimidine-2,4-(1h,3h)-dione derivatives and pharmaceutical compositions thereof and their use as inhibitors of monocarboxylate transporters
BR112017026535B1 (pt) * 2015-06-12 2023-12-19 Vettore, LLC Composto e composição farmacêutica
TWI823932B (zh) * 2018-05-11 2023-12-01 中國大陸商迪哲（江蘇）醫藥有限公司 三唑并嘧啶化合物及其在治療癌症中之用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072746A1 (en) 2001-10-16 2004-04-15 Michael Sullivan Inhibitors of monocarboxylate transport
WO2011114148A1 (en) 2010-03-17 2011-09-22 Astrazeneca Ab 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists
JP2018502874A (ja) 2015-01-22 2018-02-01 ザ スクリプス リサーチ インスティテュート プテリジンジオンモノカルボン酸トランスポータ阻害薬
WO2017196936A1 (en) 2016-05-12 2017-11-16 Regents Of The University Of Minnesota Indole and indazole cyanocinnamate compounds and therapeutic uses thereof

Also Published As

Publication number Publication date
BR112020023068A2 (pt) 2021-02-09
EP4134368A1 (en) 2023-02-15
EP3790879B1 (en) 2022-06-29
AR115384A1 (es) 2021-01-13
CN112469721A (zh) 2021-03-09
EP3790879A1 (en) 2021-03-17
ES2927244T3 (es) 2022-11-03
US20210087196A1 (en) 2021-03-25
CN115028636A (zh) 2022-09-09
WO2019215316A1 (en) 2019-11-14
PT3790879T (pt) 2022-08-26
AU2019264826A1 (en) 2020-11-26
CN115028637A (zh) 2022-09-09
US12503473B2 (en) 2025-12-23
CA3099579A1 (en) 2019-11-14
US11851432B2 (en) 2023-12-26
AU2019264826B2 (en) 2024-05-23
US11084827B2 (en) 2021-08-10
US20210340150A1 (en) 2021-11-04
KR20210013078A (ko) 2021-02-03
CN115028637B (zh) 2024-03-22
DK3790879T3 (da) 2022-08-29
US20240217980A1 (en) 2024-07-04
JP7418353B2 (ja) 2024-01-19
JP2021523177A (ja) 2021-09-02
TW202015674A (zh) 2020-05-01
TWI823932B (zh) 2023-12-01
CN112469721B (zh) 2022-06-07
MX2020012058A (es) 2021-02-26
UY38228A (es) 2019-10-31

Similar Documents

Publication Publication Date Title
KR102863374B1 (ko) 트리아졸로피리미딘 화합물 및 암 치료에서의 그의 용도
KR102919479B1 (ko) 이미다졸로닐퀴놀린 화합물 및 그의 치료적 용도
US12319670B2 (en) Compounds and methods for inhibiting JAK
EP4271673A1 (en) Indazole compounds as kinase inhibitors
AU2016323399A1 (en) 8-(6-(3-(amino)propoxy)-3-pyridyl)-1 -isopropyl-imidazo(4,5-c)quinolin-2-one derivatives as selective modulators of ataxia telangiectasia mutated (ATM) kinase for the treatment of cancer
KR20210151859A (ko) 카세인 키나아제 1ε 억제제 및 약학 조성물 및 그 응용
JP2019512512A (ja) シンノリン−４−アミン化合物およびその癌治療への使用
RU2793249C2 (ru) Триазолпиримидиновые соединения и их применение в лечении рака
HK40088382A (en) Triazolopyrimidine compounds and their use in treating cancer
HK40047025B (en) Triazolopyrimidine compounds and their use in treating cancer
HK40047025A (en) Triazolopyrimidine compounds and their use in treating cancer
HK40080418A (en) Triazolopyrimidine compounds and their use in treating cancer
HK40080417B (zh) 三唑并嘧啶化合物和其用於治疗癌症的用途
HK40080417A (en) Triazolopyrimidine compounds and their use in treating cancer
HK40047024A (en) Triazolopyrimidine compounds and their use in treating cancer
HK40096832A (en) Compounds and methods for inhibiting jak
HK40067223A (zh) 四唑取代的吡唑幷嘧啶类jak激酶抑制剂及其用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000